Extended-field Proton Therapy for Cervical Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
Proton extended field radiation therapy: Proton extended field radiation therapy
Photon extended field radiation therapy: Photon extended field radiation therapy
Study summary
Severe lymphopenia is a common complication of extended-field radiotherapy in cervical cancer, significantly impacting immune function and clinical outcomes. This study aims to evaluate whether proton therapy, with its superior dose distribution, can reduce lymphopenia and improve survival and toxicity profiles compared to photon therapy.
Eligibility
Primary outcome measure(s)
- Lymphocyte Counts — Baseline; Weeks 3-5 of radiotherapy; 2 weeks after radiotherapy completion
Lymphocyte Counts: The absolute lymphocyte count will be measured pre-treatment, during treatment, and post-treatment. Severe lymphopenia is defined as an absolute lymphocyte count \<500/μL - Immune Cell Subsets — Baseline; Weeks 3-5 of radiotherapy; 2 weeks after radiotherapy completion
Immune Cell Subsets: The percentage of CD4 (%), CD8 (%), CD19 (%), and CD16+56 (%) will be monitored to assess the immune response to therapy
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| National Taiwan University Hospital | Taipei | Taiwan | Recruiting |
| Chang Gung Memorial Hospital | Taoyuan | Taiwan | Recruiting |
More National Taiwan University Hospital trials in Taiwan
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07298642 on ClinicalTrials.gov ↗ ← All trials in Taiwan